27 results about "Human lung" patented technology

A drug testing platform for simulating a lung environment includes a microfluidic chip and a stretching device. The microfluidic chip defines a microfluidic channel structure. The microfluidic channel structure includes a test unit, a cell shunt unit and a drug shunt unit. The stretching device is configured to stretch and contract the test unit in a manner of a reciprocal motion, thereby making degree of deformation of a plurality of test area of the test unit to be same during the reciprocal motion. The drug testing platform for simulating the lung environment according to the present disclosure may configure an environment that simulates a breathing motion of a human lung, and obtain multiple results within a single test.

The present invention relates to a polysaccharide with cytotoxic activity against human colon, human lung, human melanoma and murine leukaemia tumour cells, as well as antioxidant and healing activity. The invention also relates to a method for producing the polysaccharide, its uses and applications, particularly via drugs for treating cancer and / or antioxidant and healing compositions. The polysaccharide of the present invention can be produced from biomass, particularly from fungi, and preferably from the fungus Bovistella utriformis.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

This invention discloses a method for constructing lung organoids with spontaneous vascularization and branching morphology. By optimizing the culture protocol and progressively inducing directional mesoderm, vascularized foregut endoderm, vascularized lung bud organoids, and vascularized lung organoids, lung organoids with both vascularization and branching morphology are successfully cultured, thus more realistically simulating the structural characteristics of the human lung. This invention has significant advantages: First, it can effectively induce the formation of vascularization and branching structures in lung organoids, overcoming the shortcomings of traditional lung organoids that lack vascularization and branching structures; second, by adjusting the culture method in the early stages, the uniformity of the lung organoids is significantly improved, enhancing the reliability and reproducibility of experimental results. This invention provides a more precise and efficient experimental platform for preclinical studies such as lung disease research, drug screening, and toxicology testing, and has significant application value.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

The application discloses a WUPyV infection model and a construction method and application thereof, and the construction method comprises the following steps: (1) culturing proximal differentiated lung organoids; (2) removing collagen from the lung organoids to prepare lung organoid ball suspension, mixing the lung organoid ball suspension with a WUPyV sample, and co-incubating and infecting; and (3) re-embedding the lung organoids in basement glue after infection, and continuing to culture in a basic culture medium to obtain the WUPyV infection model. The WUPyV infection model is constructed by using three-dimensional human lung organoids, WUPyV can be separated and cultured, the infection process of WUPyV in human lung organs can be better simulated and characterized, and a new infection model is provided for WUPyV infection pathogenesis and body innate immune response mechanism and interaction between viruses and host cells.

This invention discloses a biomimetic system simulating lung tissue, its manufacturing method, and a method for controlling microfluidics using this biomimetic system. The biomimetic system comprises lung epithelial cells, lung fibroblasts, and human umbilical vein endothelial cells isolated from human lungs, and is perfused with microfluidics. Gas and a fluid including culture medium can be perfused into the internal chambers of the system, simulating similar respiratory movements. Even after more than a week following perfusion, the three types of cells within the system can survive. Furthermore, pH and pO2 within the chambers can be monitored using pH and gas partial pressure sensors within the system, allowing the three types of cells to be exposed to the external environment or drugs under conditions similar to those of a living lung. This enables research in a wide range of fields, including modeling lung diseases caused by harmful substances and testing the efficacy of therapeutic drugs. It is also applicable to in vitro disease modeling and customized drug formulation.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

The invention discloses a biomarker for diagnosing pulmonary fibrosis and application thereof, and belongs to the technical field of clinical medicine. The pulmonary fibrosis biomarker lncRNA DLEU2 provided by the invention can effectively assist in diagnosing patients with pulmonary fibrosis, and activation of human lung fibroblasts can be effectively inhibited in the human lung fibroblasts through a knock-down agent sh-DLEU2.

The application discloses a culture medium for constructing a liver cancer lung metastasis microtumor model and application thereof. The application relates to the technical field of biology, and provides a culture medium for constructing a liver cancer lung metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant proteins EGF, HGF, IL-2, IL-15, R-spondin1, CXCL12, recombinant human lung surfactant proteins SP-A, SP-D, forskolin, A83-01, N-acetyl-L-cysteine, nicotinamide, N2 additives, B27 and a basic culture medium. The culture success rate of the liver cancer lung metastasis microtumor model is effectively improved.

The invention discloses a severe respiration restorer, and particularly relates to the technical field of respiration restorers, the severe respiration restorer comprises two shells, the two shells are oppositely arranged, a respiration recovery assembly is arranged between the two shells, the respiration recovery assembly comprises a connecting plate arranged between the two shells, two butt joints are arranged on one side of the connecting plate, and the two butt joints are oppositely arranged on the other side of the connecting plate. And a mixing bin is arranged on the other side of the connecting plate. Through a linkage structure of the driving motor, the eccentric block, the spring and the plug, the top plate can be alternately pushed to compress the first spring, the plug is driven to block the conveying valve, or the first spring is reset to enable the plug to be separated from the conveying valve, and the process can accurately simulate the physiological rhythm of airflow conduction during inspiration of the lung of the human body and temporary airflow closing during expiration. Compared with an existing device only capable of supplying air continuously, the device effectively avoids damage of continuous air pressure to the lung, meanwhile, it is guaranteed that carbon dioxide is smoothly discharged during expiration, and the core requirements of critical patients for respiratory support physiology and low damage are met.

1. The name of the design product: spirometer. 2. The use of the design product: the design product is used for human lung capacity breathing test. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Disclosed are a biomimic system simulating lung tissue, a method for manufacturing same, and a microfluidic control method using same, wherein the biomimic system comprises lung epithelial cells and lung fibroblasts, which are isolated from human lungs, and commercially available vascular endothelial cells, and wherein a microfluid flows through the biomimic system. Each chamber inside the corresponding system can allow a fluid, which contains gas and a medium, to flow therethrough and simulate respiration-like movement, wherein all of the three types of cells can survive inside the system even when one week or more have elapsed after through-flow of the fluid. In addition, the pH and pO2 in the chamber can be monitored by using a pH sensor and a gas partial pressure sensor inside the system, and thus the three types of cells inside the system can be exposed to external environments, drugs, and the like under the same conditions as in the lungs in vivo. Therefore, a wide range of studies including modeling of lung diseases by harmful substances and testing of therapeutic drug efficacy can be conducted, and further, the utilization to in vitro disease modeling, customized medicine prescriptions, and the like can also be made.

The invention relates to the technical field of biological medicines, and mainly relates to application of tenascin-C (Tenascinin-C, TNC) as a prevention and / or treatment target in silicosis pulmonary fibrosis. The technical problem to be solved by the invention is to provide a new target selection for prevention and / or treatment of silicosis and pulmonary fibrosis. According to the technical scheme for solving the technical problem, the invention provides the application of the TNC as a target spot for preventing and / or treating silicosis pulmonary fibrosis. It is found that TNC is highly expressed in silicosis pulmonary fibrosis lung tissue, and expression of extracellular matrix genes and protein of human lung fibroblasts can be increased; the invention further finds that the expression of Collagen I and Fibronectin in the fibroblast can be obviously reduced by knocking down the Tnc in the lung tissue fibroblast, so that the progress of pulmonary fibrosis is inhibited. The invention provides a new target selection for prevention and / or treatment of silicosis pulmonary fibrosis, and has a good application prospect.

This invention relates to a method for extracting compound Alisma alkaloid A from Alisma plantago-aquatica and its application, effectively solving the problem of extracting Alisma alkaloids from Alisma plantago-aquatica and enabling its application in the preparation of drugs for treating lung cancer. This compound, Alisma alkaloid A, significantly reduces cell viability and Bcl2 expression, induces apoptosis and mitochondrial membrane depolarization in A549 lung cancer cells, and significantly increases the expression of Bax, Caspase3, and Caspase9, without affecting normal human lung epithelial cells BEAS-2B. It has the effect of inducing apoptosis in A549 cells through the mitochondrial apoptosis pathway, thus realizing the application of Alisma alkaloid A in the preparation of drugs for treating lung cancer. The method of this invention is scientifically sound, novel, unique, and easy to operate, effectively extracting compound Alisma alkaloid A from Alisma plantago-aquatica. This compound has the effect of inducing apoptosis in A549 cells through the mitochondrial apoptosis pathway, realizing the application of Alisma alkaloid A in the preparation of drugs for treating lung cancer, and expanding the medicinal and commercial value of Alisma plantago-aquatica.

The provided is a system that provides information with high accuracy by performing voxel-based both cross-sectional and volumetric three-dimensional imaging in cancer tissues, especially in determining the necessary surgical margins of the breast tumor removed from the patient with breast cancer surgery and the presence of the tumor in the sentinel lymph node, which is the first lymph node from which the tumor drained. The provided will not be applied directly to humans and the human body, but to the tumor and / or tumorous tissue removed from the patient's cancerous organ (especially the breast). By changing the software parameters and the applied X-ray range used in breast tumors, a deep technology-based system developed can also be used in human lung, liver, pancreas, thyroid, brain, skin, small intestine, large intestine, stomach, gall bladder, esophagus, bladder, kidney, ovary, uterus, cervix, testis and prostate tumors and tumorous tissue fragments.

This invention discloses a stable human lung cell line overexpressing MLT1L, its construction method, and its applications. This invention belongs to the field of biomedicine, specifically relating to a stable human lung cell line overexpressing MLT1L, its construction method, and its applications. The substance promoting MLT1L expression of this invention can be applied to: (A1) improving the migration ability of normal lung cells; (A2) preparing products for improving the migration ability of normal lung cells; (A3) improving the invasive ability of normal lung cells; (A4) preparing products for improving the invasive ability of normal lung cells; wherein MLT1L is a long non-coding RNA with a nucleotide sequence as shown in SEQ ID No:1. This invention provides a method for constructing a stable human lung cell line overexpressing MLT1L, and overexpression of MLT1L-2034 can significantly increase the viability, proliferation, and invasive ability of Beas-2B cells.

This invention provides a biomimetic microfluidic device for simulating the three-dimensional structure of alveoli. The fabrication method includes: preparing an inverse opal membrane; bonding the inverse opal membrane to the bottom of a transwell chamber structure (with the bottom filter membrane removed); bonding the top of the transwell chamber to a perforated plate cover; inserting one end of a gas delivery tube through the perforation in the perforated plate cover into the transwell chamber; and connecting the other end to an injection pump; culturing alveolar epithelial cells and vascular endothelial cells on the front and back sides of the inverse opal membrane, respectively, to obtain the biomimetic microfluidic device. The biomimetic microfluidic device provided by this invention can achieve three-dimensional stretching under the action of a microfluidic injection pump, simulating the periodic stretch-recovery process of human lung respiratory movement in vitro. The fabrication method is simple and reliable.

The invention relates to the technical field of in-vitro cell model construction, and particularly discloses an in-vitro airway allergen presentation model and a construction method and application thereof. A double-catheter structure is prepared by adopting a 3D printing method, the inner tube is inoculated with human pulmonary epithelial cells, the bottom end of the inner tube is closed to reconstruct an airway mucosa physical barrier in a bionic manner, and the outer tube loads, induces and activates an innate immune cell subset to simulate an airway mucosa immune surveillance microenvironment; the double catheters are placed in a culture medium system containing peripheral blood mononuclear cells or / and CD4 + T cells, a culture medium containing to-be-detected allergens is added into the inner tube for multi-cell co-culture, and a highly-bionic in-vitro airway allergen presentation model is constructed. Multi-index detection of immune cell chemotaxis, T cell infiltration, cytokine secretion and T cell differentiation is achieved through immunofluorescence, ELISA and flow cytometry at the same time, diversified requirements of mechanism research and drug screening are met, and detection dimensions are comprehensive.

The invention provides a euphorbia pekinensis lipid extract and an extraction method and application thereof, the euphorbia pekinensis lipid extract is obtained through normal phase silica gel column chromatography separation and extraction, and the euphorbia pekinensis lipid extract has reverse activity in HCT-15 / Taxol human colorectal cancer-paclitaxel drug-resistant cells and A549 / Taxol human lung adenocarcinoma-paclitaxel drug-resistant cells. The obtained euphorbia pekinensis lipid extract can reverse the drug resistance of HCT-15 / Taxol and A549 / Taxol cells to chemotherapeutic drugs doxorubicin (DOX) and paclitaxel (PTX), and effectively inhibit cell proliferation. Moreover, the extract can also inhibit the excretion effect of paclitaxel (FITC-PTX), rhodamine (Rho123) and doxorubicin (DOX) in HCT-15 / Taxol and A549 / Taxol cells, and can obviously promote the release of reactive oxygen species (ROS) at the same time. The euphorbia pekinensis lipid extract extracted by the extraction method provided by the invention can be applied to anti-tumor reversal drugs or combined drugs in tumor treatment. Therefore, the clinical treatment outcome of tumor patients is expected to be improved, and a solid material foundation is laid for further developing a novel anti-tumor treatment strategy.

The invention particularly relates to a human pneumosarcoma-like carcinoma organ as well as a construction method and application thereof, and belongs to the technical field of biological medicines. The organoid is selected from TJLCI-PSC-O-1 with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C2025218 or TJLCI-PSC-O-2 with the preservation number of CCTCC NO: C2025334, or an amplified culture of an epithelial marker CK and a mesenchymal marker VIMENTIN which are stably co-expressed by the organoid. According to the construction method, a collagenase / dispersing enzyme and DNase I combined stepped enzymolysis system and a three-dimensional culture system are adopted, and high yield and long-term stable amplification of cells are realized. The model highly simulates the pulmonary sarcomatoid carcinoma pathological structure and epithelial-mesenchymal transition phenotype for the first time, can be used for in-vitro drug sensitivity test, in-vivo tumor formation model construction and drug screening, and provides a key platform for basic research and precise treatment of diseases.

The invention discloses a lung puncture robot digital twinning system facing a free breathing state. The system belongs to the technical field of digital twinning and is composed of a physical space, a digital space and a virtual-real synchronization module. The physical space is composed of a cooperative mechanical arm, a six-dimensional force sensor, a flexible puncture needle, a human lung respiration model and a vision measurement module; the vision measurement module is composed of a body surface marker, a vision camera and a vision algorithm. The digital space is a mapping model of the physical platform in the virtual environment. And the virtual-real synchronization module is used for realizing data interaction and state synchronization between the physical space and the digital space. According to the method, virtual and real synchronization of the robot puncture process can be achieved in the free breathing state of the human body, real-time monitoring, prediction and online compensation control are conducted on the dynamic positions of the lung target spot and the puncture needle, and therefore the puncture positioning error is controlled within the range of + / -2 mm, and the precision and safety of lung puncture under the free breathing condition are remarkably improved.

A lung environment-imitating drug testing platform comprises a microfluid wafer and a stretching device. The microfluidic chip defines a micro-channel structure, and the micro-channel structure comprises a test area unit, a cell sub-channel unit and a drug sub-channel unit. The stretching device comprises a clamping structure and a moving unit. The clamping structure is provided with a fixed part, a movable part spaced from the fixed part, and a groove part formed between the fixed part and the movable part; and the fixed part and the movable part are matched with each other to clamp two opposite ends of the microfluidic wafer and enable the orthographic projection of the test area unit of the microfluidic wafer to completely coincide with the groove part. According to the drug test platform simulating the lung environment, the environment simulating the respiratory movement of the human lung can be constructed, and multiple test results can be obtained through one-time test.

The application discloses a butyl tin-cyclo iridium salicylaldehyde Schiff base complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anti-cancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, chlorine, bromine, methyl, methoxy and trifluoromethoxy. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cancer cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target complex shows potential anti-proliferation activity and is superior to cisplatin. In addition, the target compound shows unique AIE emission characteristics. The target compound can target the mitochondria of A549 cells and cause the decline of the mitochondrial membrane potential, thereby showing anti-cancer activity.

The application provides a pharmaceutical composition and use. The pharmaceutical composition comprises tryptophan, salicylic acid and protocatechuic acid; the mass percentage of tryptophan is 1% to 1.5%, the mass percentage of salicylic acid is 0.4% to 0.6%, and the mass percentage of protocatechuic acid is 97.9% to 98.6% based on the mass of the pharmaceutical composition. The application first combines tryptophan, salicylic acid and protocatechuic acid in a specific manner, and uses a leading human lung organoid model to confirm the novel therapeutic effect of the pharmaceutical composition in resisting respiratory syncytial virus infection, which provides direct and feasible formula basis for developing modern traditional Chinese medicine or natural medicine with clear components and controllable quality.